The CLIP1- LTK fusion: a new oncogenic driver in non-small-cell lung cancer?

Future Oncol. 2023 Feb;19(4):273-275. doi: 10.2217/fon-2022-1232. Epub 2023 Mar 21.
No abstract available

Keywords: ALK fusion; CLIP1-LTK fusion; lorlatinib; non-small-cell lung cancer; tyrosine kinase inhibitors.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aminopyridines / therapeutic use
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents* / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / surgery
  • Humans
  • Lactams, Macrocyclic / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / surgery
  • Protein Kinase Inhibitors / therapeutic use
  • Receptor Protein-Tyrosine Kinases

Substances

  • Antineoplastic Agents
  • Anaplastic Lymphoma Kinase
  • Protein Kinase Inhibitors
  • Aminopyridines
  • Lactams, Macrocyclic
  • LTK protein, human
  • Receptor Protein-Tyrosine Kinases